




PHARMACEUTICAL 2021

Urovant Sciences Ltd.
Rank 368 of 402





PHARMACEUTICAL 2021

Urovant Sciences Ltd.
Rank 368 of 402

The relative strengths and weaknesses of Urovant Sciences Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Urovant Sciences Ltd. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 13% points. The greatest weakness of Urovant Sciences Ltd. is the variable Assets, Current, reducing the Economic Capital Ratio by 149% points.

The company's Economic Capital Ratio, given in the ranking table, is -267%, being 314% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	58,318
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,931
Liabilities, Non-Current	3,086
Other Assets	3,767
Other Compr. Net Income	183
Other Expenses	65
Other Liabilities	87,284
Other Net Income	-7,944
Other Revenues	0
Property and Equipment	1,210
Research and Development	92,437
Selling, General and Administrative Expense	46,299

Output Variable	Value in 1000 USD
Assets	63,295
Liabilities	121,301
Expenses	138,801
Revenues	0
Stockholders Equity	-58,006
Net Income	-146,745
Comprehensive Net Income	-146,654
Economic Capital Ratio	-267%